Join BIOCYTOGEN at World ADC London 2025

Join BIOCYTOGEN at World ADC London 2025

We’re excited to announce our participation as an exhibitor at World ADC London Showcase 2025! From March 3rd to 6th in London, UK, this leading event serves as a critical platform for biotechnology companies to highlight groundbreaking advancements. With unparalleled opportunities for direct engagement, World ADC fosters meaningful connections between innovators, investors, and biopharmaceutical leaders, driving collaboration and progress in life sciences.

What is World ADC London 2025?

World ADC London is a leading conference that bridges the gap between biotechnology companies—from private startups to micro- and mid-cap organizations—and influential investors and biopharmaceutical executives. Bringing together over 700 professionals for four days of insightful learning, the event offers a deep dive into emerging industry trends and unparalleled networking opportunities. Engage with established pharma giants like Daiichi Sankyo, AstraZeneca, and GlaxoSmithKline, collaborate with pioneering biotechs such as ADC Therapeutics, OBI Pharma, and Zymeworks, and connect with top-tier solution providers shaping the future of ADC development.

Event Overview  

Date: March 3rd – 6th 

Venue: Novotel London West. 1 Shortlands Hammersmith International Ctre, London W6 8DR, UK

Event Schedule

The World ADC London 2025 in London, UK will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the World ADC London 2025 agenda.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).

We look forward to seeing you at the World ADC London 2025 in London, UK!

Share:

Back to top
WordPress Double Opt-in by Forge12